On the other hand, another recent study based on in vitro DLBCL model showed that a loss of KLHL14, a negative BCR regulator found to be mutated in about 10% of ABC-DLBCL, induces the NF-κB pathway by activating the MYD88-TLR9-BCR super-complex, which confers relative resistance to the first-in-class BTKi ibrutinib [45]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.